However, NSCLC patients with BRAF non-V600 mutations show much less sensitivity than V600 to these drugs, and novel BRAF kinase inhibitors are tested in clinical trials (Bracht et al., 2019[7]; Yan et al., 2022[94]). Here, BRAF is linked to non-small cell lung carcinoma.